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Letter to the Editor 
ECT IN TREATMENT RESISTANT 
SCHIZOPHRENIA 
Sir, 
We read with interest the report on 
efficacy of electro convulsive therapy (ECT) 
in treatment resistant schizophrenia 
(Goswami et al 2003). A substantial pro-
portion of patients with schizophrenia re-
main resistant to treatment. Hence a need 
for additional/alternative treatments in such 
situations is strongly felt by psychiatrists. 
Authors' effort to address this issue is 
therefore timely and welcome. 
However, some methodological flaws in 
the report make authors' claim of ECT 
being efficacious in treatment-resistant 
schizophrenia difficult to accept. Although 
they have used a robust design, randomized, 
appropriate analysis, two-way RMANOVA, 
was not applied. Instead they used one-way 
RMANOVA separately for ECT and sham-
ECT groups. Both groups showed about 
20% reduction in BPRS scores. This was 
significant in ECT but not sham-ECT 
group. This might well be due to a 30% 
smaller sample size and hence type-II error 
in the latter group. 
Either group did not improve after the trial 
as indicated by CGI scores. Their findings 
hence suggest that ECT may not confer 
advantage in schizophrenia patients who 
have shown inadequate response to drugs. 
This supports Paul et al (1997) too reported 
similar finding from this country in a recent 
report. 
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IN REPLY 
Sir, 
We are pleased that Jagadisha and col-
leagues have taken an interest in our paper 
that suggests that ECT add-on may be 
beneficial to those patients with schizophre-
nia who do not respond adequately to 
antipsychotic drugs alone. Quite obviously, 
the study suffers from being underpowered. 
Hence, the points raised by these authors 
are appreciated and we recommend that it 
should be read and interpreted with caution. 
As regards the statistical exercise, we do not 
have too many troubles with the way we 
went around assessing the available data 
using one-way RMANOVA, though we 
agree that two-way RMANOVA would have 
been more stylish. 
The main reason for us to conclude the 
way we did, in favour of ECT add-on 
treatment, is that, apart from the primary 
measures, even the secondary measures 
were found to favour the treatment group. 
Further, the improvement in patients re-
ceiving sham-ECT was restricted to the 
very first week only. Afterwards, no 
improvement could be seen in these 
patients. No clinician expects a sudden and 
robust change of scores in a population 
of treatment resistant schizophrenics so 
early in a course of ECTs. Thus, the 
improvement seen can be attributed to 
factors other than therapeutic; these include 
improvement in EPS, removal of non-
compliance through supervised medica-
tion, removal of the patient from a high 
EE environment, among others. On the 
other hand, the real-ECT group showed 
consistent improvement over time, but 
the magnitude of improvement after ECTs 
was somewhat smaller, thus we did not 
find changes in CGI. 
This observation has several clinical and 
methodological implications. It shows why 
it has now become customary, particularly 
in the context of therapy resistant schizo-
phrenia, to institute a high-potency neu-
roleptic such as haloperidol. Second, it 
demonstrates that we cannot expect sharp 
treatment effects. Perhaps, it also goes to 
demonstrate and explain the reasons for 
differences in literature on the subject. 
It is extremely difficult to find able and 
willing patients of rigorously defined treat-
ment resistant schizophrenia, and it is very 
difficult to keep them going in a study like 
this. Therefore, pooling of cases across 
several centres, employing a very similar 
design may be more rewarding. 
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